Scarica l'app Stockscreener
131.26
0.49%
-0.65
Dopo l'orario di chiusura:
131.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$131.91
Aprire:
$132.46
Volume 24 ore:
1.82M
Relative Volume:
1.27
Capitalizzazione di mercato:
$277.28B
Reddito:
$54.45B
Utile/perdita netta:
$14.42B
Rapporto P/E:
17.90
EPS:
7.333
Flusso di cassa netto:
$17.15B
1 W Prestazione:
+3.89%
1M Prestazione:
+0.77%
6M Prestazione:
+25.02%
1 anno Prestazione:
+26.94%
Intervallo 1D:
$130.30
$132.76
Intervallo di 1 settimana:
$126.29
$134.00
Portata 52W:
$96.06
$134.00
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 - Benzinga
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com
Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm
Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news
Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):